Pharmacological Characterization of Histone Deacetylase Inhibitor and Tumor Cell-Growth Inhibition Properties of New Benzofuranone Compounds

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|11|8|919-928

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.11, Iss.8, 2011-01, pp. : 919-928

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma

By Duvic Madeleine   Vu Jenny  

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 7, 2007-07 ,pp. : 1111-1120

Informa Healthcare

Access to resources Recommend Favorite

Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor

By Gimsing Peter  

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 4, 2009-04 ,pp. : 501-508

Informa Healthcare

Access to resources Recommend Favorite

Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells

By Oh Eun-Taex  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 435-442

Springer Publishing Company

Access to resources Recommend Favorite

Effect of a Histone Deacetylase Inhibitor on Human Cardiac Mass

By Shizukuda Yukitaka   Piekarz Richard   Bates Susan   Sachdev Vandana   Finkel Toren   Rosing Douglas  

Cardiovascular Drugs and Therapy, Vol. 19, Iss. 1, 2005-01 ,pp. : 89-90

Springer Publishing Company

Access to resources Recommend Favorite

Romidepsin: a novel histone deacetylase inhibitor for cancer

By Bertino Erin M   Otterson Gregory A  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 8, 2011-08 ,pp. : 1151-1158

Informa Healthcare

Access to resources Recommend Favorite